about
Budesonide for induction of remission in Crohn's diseaseVedolizumab for induction and maintenance of remission in Crohn’s diseaseAnti-MAdCAM antibody for induction of remission in ulcerative colitisAnti-IL-12/23p40 antibodies for induction of remission in Crohn's diseaseAdverse effects of biologics: a network meta-analysis and Cochrane overviewSargramostim (GM-CSF) for induction of remission in Crohn's diseaseThalidomide and thalidomide analogues for induction of remission in Crohn's diseaseTumor necrosis factor-alpha antibody for maintenance of remission in Crohn's diseaseBudesonide for induction of remission in Crohn's diseaseCertolizumab pegolVedolizumab for the treatment of ulcerative colitis and Crohn's diseasePredicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel diseaseAdvances in the development of new biologics in inflammatory bowel diseaseUstekinumab for the treatment of Crohn's disease: can it find its niche?Medical Therapy of Perianal Crohn's DiseaseSystematic review: The safety and efficacy of hyperbaric oxygen therapy for inflammatory bowel diseaseProfile of ustekinumab and its potential in patients with moderate-to-severe Crohn's disease.Anti-TNF therapy for juvenile idiopathic arthritis-related uveitisA review of the impact of biologics on surgical complications in Crohn's diseaseReview article: anti-adhesion therapies for inflammatory bowel diseaseInflammatory pathways of importance for management of inflammatory bowel diseaseStem cell therapy in inflammatory bowel disease: A promising therapeutic strategy?Redeeming an old foe: protective as well as pathophysiological roles for tumor necrosis factor in inflammatory bowel diseaseUstekinumab in Crohn's disease: evidence to date and place in therapyThe Role of Laboratory Tests in Crohn's DiseaseCurrent therapy of pediatric Crohn's diseaseBiomarkers as potential treatment targets in inflammatory bowel disease: A systematic reviewSevere and steroid-resistant Crohn's diseaseThe JNK inhibitor XG-102 protects against TNBS-induced colitis.Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview.Ustekinumab for the treatment of Crohn's disease.Efficacy and safety of certolizumab pegol for Crohn's disease: a systematic review and meta-analysis.Inflammatory bowel disease: perioperative pharmacological considerations.Biologics in inflammatory bowel disease: what are the data?Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study.Biological treatment of Crohn's disease.Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn's disease: a randomized multicenter trial (LIR!C-trial).Inflammatory Bowel Disease (IBD) pharmacotherapy and the risk of serious infection: a systematic review and network meta-analysisNew Data on the Use of Biologic Agents for Crohn's Disease and Ulcerative Colitis: Highlights from the 2009 CCFA Advances in IBD MeetingRetrospective cohort study of anti-tumor necrosis factor agent use in a veteran population
P2860
Q24187309-D582D749-8F24-4610-BD84-E4C8D79BC807Q24187571-C106F2F5-A2E7-4C64-856F-27C8540E73EFQ24187593-A6B06909-0F80-4B49-84E6-A9DCB5E5EB90Q24188040-0031FF82-BF6C-47AD-9A49-D7220B879A6FQ24234197-E668E96F-A4DD-44CA-8894-A3210350DFFAQ24235068-6E4C9200-1C11-4603-A73D-44C79C848ABDQ24241766-8D91699E-1867-4BA9-A380-92C7F1BDF137Q24242101-88D44758-22D6-4841-8319-A3931D9513CCQ24242729-99D3D3FD-11E7-415E-9D1F-0D3C56C206AEQ24625401-ACB8137D-9256-40CD-8345-53C92D2F7F9EQ24630083-57F7CA91-2640-4681-B12D-EF446CF477E6Q26745721-46E72080-C8CE-4872-9ACB-72D865E27F88Q26745782-3F57EEED-3320-4603-8843-C0B2CFB13CF9Q26771890-CDD44309-FB97-4655-BCCF-7A825EC3345DQ26777722-2CFB4DC5-BE5B-4118-B63F-0F5FE260D78EQ26823547-D97D5050-7A0D-41AA-873B-FB3C3BC6FB2BQ26825174-3ADA007B-A502-4F9C-828D-D958766E042AQ26849811-295E11D7-073A-4F98-9CEE-1F6C738178C4Q26865009-4217EFD6-08D4-41BE-959F-41E0540DFBEBQ26999705-DCB8F854-07D5-4A2B-9D1B-8CF427F2FEB4Q27005445-074E1A2C-810D-4FF4-A0F1-A6D68E8C8D9DQ27022380-D3B79A92-435D-4D5A-8676-9F0C3228ABC3Q27027630-326452FF-B4BE-425A-86A8-C7330D0F8CAAQ28073787-17F1CBE2-022B-4C53-8D48-D2A5B94E1094Q28075045-13C5246B-6186-4A7A-84B1-2E6CF5018905Q28081919-8B451C59-BC35-45CE-956C-37328AF9DE9EQ28087434-7ED3D582-07E0-410B-AA63-CA138D5D1770Q28266806-E017EF71-A2C8-424B-B6DC-BA62AB4A93E1Q28481470-791E017C-6093-4B9A-B251-FA547B148662Q30235581-55BE7A8D-A350-441F-8128-6363C726B29BQ30390909-73E5E3FF-FFAC-4CF9-B1C6-8441657C3E49Q30486142-3885C2DC-E803-4BF2-91CB-6CD3E68D7AD2Q30502980-2E3A4316-2990-413E-86C4-25587A2CA31BQ31017419-82756D3D-2707-46F2-9CEA-6E0C5A729F55Q31113830-31992AF8-A0CA-45B5-8E84-CCF5A524D0D1Q33354991-DF0D32BB-CA36-407C-8267-2B5121D69FA5Q33362566-4CD8F74E-81B2-4A62-8F45-09BC67579310Q33564492-18DEE1A3-C474-47D7-9957-37C6E540C043Q33612263-44796C42-3545-4800-9B05-868AECD14D3AQ33667897-574355E2-5F77-445C-90C9-0EC7C70FF0CB
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Certolizumab pegol for the treatment of Crohn's disease
@ast
Certolizumab pegol for the treatment of Crohn's disease
@en
Certolizumab pegol for the treatment of Crohn's disease
@nl
type
label
Certolizumab pegol for the treatment of Crohn's disease
@ast
Certolizumab pegol for the treatment of Crohn's disease
@en
Certolizumab pegol for the treatment of Crohn's disease
@nl
prefLabel
Certolizumab pegol for the treatment of Crohn's disease
@ast
Certolizumab pegol for the treatment of Crohn's disease
@en
Certolizumab pegol for the treatment of Crohn's disease
@nl
P2093
P50
P3181
P356
P1476
Certolizumab pegol for the treatment of Crohn's disease
@en
P2093
David Mason
Pieter J Honiball
Ralph Bloomfield
Simeon Stoinov
Stefan Schreiber
P304
P3181
P356
10.1056/NEJMOA067594
P407
P577
2007-07-19T00:00:00Z